Rapid, automated capture screening of influenza antiviral targets using Nicoya Alto® digital surface plasmon resonance


Rapid screening and kinetic characterization of medium sized libraries is commonly seen as one of the initial steps within the drug discovery process. Screening assays are used to quickly test and select the best candidates that bind to or affect a desired target. Label-free surface plasmon resonance (SPR) is often used to conduct medium to high-throughput screening to test for real-time binding activity of a variety of biological and chemical compounds. Capture screening is a new assay offered on Alto™, Nicoya’s digital microfluidics (DMF) based SPR instrument.

The simple, pre-configured capture screening protocol allows users to establish binding activity of up to 96 interactions on one cartridge with only 2 µL of sample. This application note demonstrates that Alto can bring rapid assay development and minimized instrument maintenance to accelerate your antibody identification and characterization flow, with intuitive software features. This feature is tailored to expedite assay development in biopharmaceutical lead discovery, antibody engineering and preclinical assay development.

Series of sensorgrams collected for a single lane of the capture screening assay with high throughput expansion turned on. The sensorgrams show the capture (or absence of capture) of the ligand followed by washing with buffer and then binding (or absence of binding) of the antigen. Antibodies loaded in wells D1-I1 are tested against both antigens, resulting in an overlay of twelve curves for each lane of test, and 96 overall.